Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

"Kidneys" Том 9, №1, 2020

Back to issue

Multimodal imaging of prostate cancer

Authors: Король П.О.(1, 2), Ткаченко М.М.(3), Щербіна О.В.(2)
(1) — Київська міська клінічна лікарня № 12, м. Київ, Україна
(2) — Національна медична академія післядипломної освіти імені П.Л. Шупика, м. Київ, Україна
(3) — Національний медичний університет імені О.О. Богомольця, м. Київ, Україна

Categories: Nephrology

Sections: Specialist manual

print version


Summary

В огляді літератури розглянуті ключові питання клінічного застосування методів мультимодальної візуалізації раку передміхурової залози (РПЗ). Світова наукова спільнота на сучасному етапі докладає інтенсивних зусиль для розробки інструментів стратифікації ризику для допомоги в прийнятті клінічних рішень та оптимізації догляду за пацієнтами з РПЗ. Мультимодальна візуалізація відіграє ключову роль у веденні пацієнтів з РПЗ завдяки її неінвазивному підходу до оцінювання наявності та масштабів первинного пухлинного процесу, метастатичного поширення. Активно впроваджується в клінічну практику перспективний напрямок ядерної медицини — тераностика. Основний принцип тераностики полягає в тому, щоб «бачити, що ви лікуєте», поєднуючи діагностичні маркери з терапевтичними радіолігандами.

В обзоре литературы рассмотрены ключевые вопросы клинического применения методов мультимодальной визуализации рака предстательной железы (РПЖ). Мировое научное сообщество на современном этапе прикладывает интенсивные усилия для разработки инструментов стратификации риска, помогающих в принятии клинических решений и оптимизации диагностического ведения пациентов с РПЖ. Мультимодальная визуализация играет ключевую роль в управлении пациентами с РПЖ благодаря ее неинвазивному подходу к оценке наличия и масштабов первичного опухолевого процесса, метастатического распространения. Активно внедряется в клиническую практику перспективное направление ядерной медицины — тераностика. Основной принцип тераностики заключается в том, чтобы «видеть, что вы лечите», сочетая диагностические маркеры с терапевтическими радиолигандами.

The literature review presents key issues of the clinical application of multimodal imaging methods in prostate cancer. The world scientific community at the present stage exerts intensive efforts to develop risk stratification tools to help making clinical decisions and optimizing the care of patients with prostate cancer. Multimodal imaging plays a key role in the management of prostate cancer patients for its non-invasive approach to assessing the presence and extent of the primary tumor process, metastatic spread. A promising area of nuclear medicine, theranostics, is being actively introduced into clinical practice. The basic principle of theranostics is to “see that you are treating” by combining diagnostic markers with therapeutic radioligands.


Keywords

магнітно-резонансна томографія; позитронно-емісійна томографія; радіофармпрепарат; рак передміхурової залози; огляд

магнитно-резонансная томография; позитронно-эмиссионная томография; радиофармпрепарат; рак предстательной железы; обзор

magnetic resonance imaging; positron emission tomography; radiopharmaceutical; prostate cancer; review


For the full article you need to subscribe to the magazine.


Bibliography

1. Yadav S.S., Stockert J.A., Hackert Vet alIntratumor heteroge neity in prostate cancer. Urol Oncol. 2018. 36. Р. 349-360. DOI: 10.1016/j.urolonc.2018.05.008.

2. Freitag M.T., Radtke J.P., Afshar-Oromieh A. et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur. J. Nucl. Med. Mol. Imaging. 2017. 44. Р. 776-787. DOI: 10.1007/s00259-016-3594-z. Epub 2016 Dec 17.

3. Korol P., Tkachenko M. The role of radioactive methods in the diagnostic type of hydronephrosis in clean-up workers of chornodil accident. Problems of radiation medicine and radiobiology. 2018. 23. Р. 351-358 (in Ukraine).

4. Park S.Y., Zacharias C., Harrison C. et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018. 288. Р. 495-505. DOI: 10.1148/radiol.2018172232. Epub 2018 May 22.

5. Kasivisvanathan V., Rannikko A.S., Borghi M. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 2018. 378. Р. 1767-1777. DOI: 10.1056/NEJMoa1801993.

6. Torabi M., Aquino S.L., Harisinghani M.G. Current concepts in lymph node imaging. J. Nucl. Med. 2004. 45. Р. 1509-1518.

7. Armstrong A.J., Anand A., Edenbrandt L. et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018. 4. Р. 944-951. DOI: 10.1001/jamaoncol.2018.1093.

8. von Eyben F.E., Roviello G., Kiljunen T. et al. Third-line treatment and177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur. J. Nucl. Med. Mol. Imaging. 2018. 45. Р. 496-508. DOI: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16.

9. Fanti S., Minozzi S., Antoch G. et al. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol. 2018. Vol. 19. P. 696-708. DOI: 10.1016/S1470-2045(18)30604-1.

10. Metser U., Chua S.S., Ho B. et al. The contribution of multiparametric pelvic &whole body MR to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy. J. Nucl. Med. March 22, 2019 [Epub ahead of print]. DOI: 10.2967/jnumed.118.225185. Epub 2019 Mar 22.

11. Padhani A.R., Lecouvet F.E., Tunariu N. et al. Metastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur. Urol. 2017. 71. Р. 81-92. DOI: 10.1016/j.eururo.2016.05.033. Epub 2016 Jun 14.

12. Zacho H.D., Nielsen J.B., Afshar-Oromieh A. et al. Prospective comparison of 68Ga-PSMA PET/CT,18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2018. 45. Р. 1884-1897. DOI: 10.1007/s00259-018-4058-4. Epub 2018 Jun 6.

13. Padhani A.R., Lecouvet F.E., Tunariu N. et al. Rationale for modernising imaging in advanced prostate cancer. Eur. Urol. Focus. 2017. 3. Р. 223-239. DOI: 10.1016/j.euf.2016.06.018. Epub 2016 Jul 15.

14. Donohoe K.J., Cohen E.J., Giammarile F. et al. Appropriate use criteria for bone scintigraphy in prostate and breast cancer: summary and excerpts. J. Nucl. Med. 2017. 58(4). Р. 14-17.

15. Wibmer A.G., Burger I.A., Sala E. et al. Molecular imaging of prostate cancer. Radiographics. 2016. 36. Р. 142-159. DOI: 10.1148/rg.2016150059. Epub 2015 Nov 20.

16. Jadvar H. Is there use for FDG-PET in prostate cancer? Semin. Nucl. Med. 2016. 46. Р. 502-506. DOI: 10.1053/j.semnuclmed.2016.07.004. Epub 2016 Sep 3.

17. Shen G., Liu J., Hao Z. et al. Is18F-FDG PET/CT a useful tool in prostate cancer? [abstract]. J. Nucl. Med. 2017. 58(suppl. 1). Р. 1077.

18. Vargas H.A., Wassberg C., Fox J.J. et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014. 271. Р. 220-229. DOI: 10.1148/radiol.13130625. Epub 2013 Nov 18.

19. Segall G., Delbeke D., Stabin M.G. et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J. Nucl. Med. 2010. 51. Р. 1813-1820. DOI: 10.2967/jnumed.110.082263.

20. Löfgren J., Mortensen J., Rasmussen S.H. et al. A prospective study comparing 99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with 18F-fluoride PET/CT and18F-fluoride PET/MRI for diagnosing bone metastases. J. Nucl. Med. 2017. 58. Р. 1778-1785. DOI: 10.2967/jnumed.116.189183. Epub 2017 Aug 10.

21. Schwarzenböck S., Souvatzoglou M., Krause B.J. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012. 2. Р. 318-330. DOI: 10.7150/thno.4008. Epub 2012 Mar 15.

22. Hodolic M. Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol. Oncol. 2011. 45. Р. 17-21. DOI: 10.2478/v10019-010-0050-8.

23. Calais J., Ceci F., Nguyen K. et al. Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer bio-chemical recurrence after primary prostatectomy [abstract]. J. Clin. Oncol. 2019. 37(suppl.). Р. 15. DOI: 10.1200/JCO.2019.37.7.

24. Burger I.A., Müller J., Donati O.F. et al. 68Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU. J. Nucl. Med. 2019. 60. Р. 1118-1123. DOI: 10.2967/jnumed.118.221564. Epub 2019 Jan 25.

25. Schuster D.M., Savir-Baruch B., Nieh P.T. et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and111In-capromab pendetide SPECT/CT. Radiology. 2011. 259. Р. 852-861. DOI: 10.1148/radiol.11102023. Epub 2011 Apr 14.

26. Bostwick D.G., Pacelli A., Blute M. et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998. 82. Р. 2256-2261. DOI: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s.

27. Oh S.W., Cheon G.J.. Prostate-specific membrane antigen PET imaging in prostate cancer: opportunities and challenges. Korean J. Radiol. 2018. 19. Р. 819-831. DOI: 10.3348/kjr.2018.19.5.819. Epub 2018 Aug 6.

28. Chang S.S., O’Keefe D.S., Bacich D.J. et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 1999. 5. Р. 2674-2681.

29. Kesler M., Levine C., Hershkovitz D. et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J. Nucl. Med. July 12, 2018 [Epub ahead of print]. DOI: 10.2967/jnumed.118.214833. [Epub ahead of print].

30. Giesel F.L., Knorr K., Spohn F. et al. Detection efficacy of 18F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J. Nucl. Med. 2019. 60. Р. 362-368. DOI: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

31. Rathkopf D., Scher H.I. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 2013. 19. Р. 43-49. DOI: 10.1097/PPO.0b013e318282635a.

32. Larson S.M., Morris M., Gunther I. et al. Tumor localization of 16b-18F-fluoro-5a-dihydrotestosterone versus18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 2004. 45. Р. 366-373.

33. Vargas H.A., Kramer G.M., Scott A.M. et al. Reproducibility and repeatability of semiquantitative18F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: a prospective multicenter study. J. Nucl. Med. 2018. 59. Р. 1516-1523. DOI: 10.2967/jnumed.117.206490. Epub 2018 Apr 6.

34. Eiber M., Weirich G., Holzapfel K. et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur. Urol. 2016. 70. Р. 829-836. DOI: 10.1016/j.eururo.2015.12.053. Epub 2016 Jan 18.

35. Hicks R.M., Simko J.P., Westphalen A.C. et al. Diagnostic accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology. 2018. 289. Р. 730-737. DOI: 10.1148/radiol.2018180788. Epub 2018 Sep 18.

36. Turkbey B., Mani H., Shah V. et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J. Urol. 2011. 186. Р. 1818-1824. DOI: 10.1016/j.juro.2011.07.013. Epub 2011 Sep 25.

37. Weinreb J.C., Barentsz J.O., Choyke P.L. et al. PI-RADS prostate imaging: reporting and data system-2015, version 2. Eur. Urol. 2016. 69. Р. 16-40. DOI: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.

38. Ahmed H.U., El-Shater Bosaily A., Brown L.C. et al. Diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017. 389. Р. 815-822. DOI: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.

39. Moldovan P.C., Van den Broeck T., Sylvester R. et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur. Urol. 2017. 72. Р. 250-266. DOI: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21.

40. Mohammadian Bajgiran A., Afshari Mirak S., Shakeri S. et al. Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference. Abdom. Radiol. (NY). 2019. 44. Р. 1052-1061. DOI: 10.1007/s00261-018-1823-6.

41. Borofsky S., George A.K., Gaur S. et al. What are we missing? False-negative cancers at multiparametric MR imaging of the prostate. Radiology. 2018. 286. Р. 186-195. DOI: 10.1148/radiol.2017152877. Epub 2017 Oct 20.

42. Sala E., Akin O., Moskowitz C.S. et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006. 238. Р. 929-937. DOI: 10.1148/radiol.2383050657.

43. de Rooij M., Hamoen E.H., Witjes J.A. et al. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic metaanalysis. Eur. Urol. 2016. 70. Р. 233-245. DOI: 10.1016/j.eururo.2015.07.029. Epub 2015 Jul 26.

44. Mühlematter U.J., Becker K.S.A., Müller J. et al. Detection of extracapsular extension in high risk prostate cancer patients: multiparametric MRI vs.68Ga-PSMA-11 PET/MRI. Paper presented at: 2019 European Congress of Radiology; February 28, 2019; Vienna, Austria.

45. Ross H.M., Kryvenko O.N., Cowan J.E. et al. Do adenocarcinomas of the prostate with Gleason score (GS) #6 have the potential to metastasize to lymph nodes? Am. J. Surg. Pathol. 2012. 36. Р. 1346-1352. DOI: 10.1097/PAS.0b013e3182556dcd.

46. Briganti A., Larcher A., Abdollah F. et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur. Urol. 2012. 61. Р. 480-487. DOI: 10.1016/j.eururo.2011.10.044. Epub 2011 Nov 7.

47. Eggener S.E., Scardino P.T., Walsh P.C. et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 2011. 185. Р. 869-875. DOI: 10.1016/j.juro.2010.10.057. Epub 2011 Jan 15.

48. Hövels A.M., Heesakkers R.A.M., Adang E.M. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol. 2008. 63. Р. 387-395. DOI: 10.1016/j.crad.2007.05.022. Epub 2008 Feb 4.

49. Evangelista L., Guttilla A., Zattoni F. et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur. Urol. 2013. 63. Р. 1040-1048. DOI: 10.1016/j.eururo.2012.09.039. Epub 2012 Sep 25.

50. Hofman M.S., Murphy D.G., Williams S.G. et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018. 122. Р. 783-793. DOI: 10.1111/bju.14374. Epub 2018 Jun 3.

51. Selnæs K.M., Kruger-Stokke B., Elschot M. et al. 18F-fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur. Radiol. 2018. 28. Р. 3151-3159. DOI: 10.1007/s00330-017-5213-1. Epub 2018 Jan 2.

52. Grubmüller B., Baltzer P., Hartenbach S. et al. PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin. Cancer Res. 2018. 24. Р. 6300-6307. DOI: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23.

53. Giesel F.L., Fiedler H., Stefanova M. et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015. 42. Р. 1794-1800. DOI: 10.1007/s00259-015-3106-6. Epub 2015 Jul 11.

54. Maurer T., Gschwend J.E., Rauscher I. et al. Diagnostic efficacy of 68 gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J. Urol. 2016. 195. Р. 1436-1443. DOI: 10.1007/s00259-015-3106-6. Epub 2015 Jul 11.

55. Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J. Clin. Oncol. 2016. 34. Р. 1402-1418. DOI: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

56. Sweeney C.J., Chen Y.H., Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015. 373. Р. 737-746. DOI: 10.1056/NEJMoa1503747.

57. Pyka T., Okamoto S., Dahlbender M. et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur. J. Nucl. Med. MolImaging. 2016. 43. Р. 2114-2121. DOI: 10.1007/s00259-016-3435-0.

58. Mottet N., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 2017. 71. Р. 618-629. DOI: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.

59. Briganti A., Karnes R.J., Joniau S. et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur. Urol. 2014. 66. Р. 479-486. DOI: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

60. Oppenheimer D.C., Weinberg E.P., Hollenberg G.M. et al. Multiparametric magnetic resonance imaging of recurrent prostate cancer. J. Clin. Imaging. Sci. 2016. 6. Р. 18. DOI: 10.4103/2156-7514.181494. eCollection 2016.

61. Akin O., Gultekin D.H., Vargas H.A. et al. Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur. Radiol. 2011. 21. Р. 1970-1978. DOI: 10.1007/s00330-011-2130-6.

62. Donati O.F., Jung S.I., Vargas H.A. et al. Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology. 2013. 268. Р. 440-450. DOI: 10.1148/radiol.13122149. Epub 2013 Mar 12.

63. Wu L.M., Xu J.R., Gu H.Y. et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin. Oncol. (R. Coll. Radiol.). 2013. 25. Р. 252-264.

64. Sandgren K., Westerlinck P., Jonsson J.H. et al. Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy: a systematic review. Eur. Urol. Focus. November 11, 2017 [Epub ahead of print]. DOI: 10.1016/j.euf.2017.11.001. Epub 2017 Nov 11.

65. Barchetti F., Stagnitti A., Megna V. et al. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur. Rev. Med. Pharmacol. Sci. 2016. 20. Р. 3770-3776.

66. Afshar-Oromieh A., Zechmann C.M., Malcher A. et al. Comparison of PET imaging with a68Ga-labelled PSMA ligand and18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014. 41. Р. 11-20.

67. Tan N., Bavadian N., Calais J. et al. Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. J. Urol. 2019. 202. Р. 231-240. DOI: 10.1097/JU.0000000000000198. Epub 2019 Jul 8.

68. Bravaccini S., Puccetti M., Bocchini M. et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. Sci. Rep. 2018. 8. Р. 4254. DOI: 10.1038/s41598-018-22594-1.

69. Andriole G.L., Kostakoglu L., Chau A. et al. The impact of positron emission tomography with18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J. Urol. 2019. 201. Р. 322-331. DOI: 10.1016/j.juro.2018.08.050.

70. Jilg C.A., Drendel V., Rischke H.C. et al. Detection rate of 18F-choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for prostate cancer lymph node metastases with direct link from PET to histopathology: dependence on the size of tumor deposits in lymph nodes. J. Nucl. Med. 2019. 60. Р. 971-977. DOI: 10.2967/jnumed.118.220541. Epub 2019 Jan 25.

71. Fendler W.P., Calais J., Eiber M. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019. 5. Р. 856-863. DOI: 10.1001/jamaoncol.2019.0096.

72. Fox J.J., Gavane S.C., Blanc-Autran E. et al. Positron emission tomography/computed tomography — based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol. 2018. 4. Р. 217-224. DOI: 10.1001/jamaoncol.2017.3588.

73. Pandit-Taskar N., Veach D.R., Fox J.J. et al. Evaluation of castration-resistant prostate cancer with androgen receptor — axis imaging. J. Nucl. Med. 2016. 57(suppl). Р. 73-78. DOI: 10.2967/jnumed.115.170134.

74. Fendler W.P., Rahbar K., Herrmann K. Et al. 177Lu-PSMA radioligand therapy for prostate cancer. J. Nucl. Med. 2017. 58. Р. 1196-1200. DOI: 10.2967/jnumed.117.191023. Epub 2017 Jun 29.

75. Ghafoor S., Burger I.A., Vargas A.H. Multimodality Imaging of Prostate Cancer. J. Nucl. Med. 2019. 60(10). Р. 1350-1358. DOI: 10.2967/jnumed.119.228320. Epub 2019 Sep 3.

76. Rahbar K., Ahmadzadehfar H., Kratochwil C. et al. German multicenter study investigating177 Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J. Nucl. Med. 2017. 58. Р. 85-90. DOI: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.

77. Hofman M.S., Violet J., Hicks R.J. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018. 19. Р. 825-833. DOI: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.

78. Ceder Y., Bjartell A., Culig Z. et al. The molecular evolution of castration-resistant prostate cancer. Eur. Urol. Focus. 2016. 2. Р. 506-513. DOI: 10.1016/j.euf.2016.11.012. Epub 2016 Dec 9.

79. Heitkötter B., Steinestel K., Trautmann M. et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018. 9. Р. 9867-9874.

80. Pezaro C., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 2014. 65. Р. 270-273. DOI: 10.1016/j.eururo.2013.10.055. Epub 2013 Nov 22.

81. Король П.О., Ткаченко М.М. Сучасні напрямки радіонуклідної діагностики і терапії хворих на рак передміхурової залози. Лучевая диагностика. Лучевая терапия. 2018. 3. С. 59-70. (in Ukraine).


Back to issue